Exiqon A/S
Exiqon launches advanced on-line tool for design of LNA™ gapmers for inhibition of mRNA and lncRNA

Exiqon A/S 

03.09.2013 15:22
---------------------------------------------------------------------------

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced an extension to the LNA(TM) longRNA GapmeR
product line with the launch of a novel on-line bioinformatics tool for the
design of custom LNA(TM)-gapmer antisense oligonucleotides for specific and
efficient inhibition of mRNA and lncRNA. 

The new on-line LNA(TM) gapmer design tool allows scientists to effortlessly
design optimal LNA(TM) gapmers through a simple and intuitive interface. 

The tool provides a ranked list of LNA(TM) gapmer designs that takes into account
more than 30 design criteria in the evaluation of more than 100,000 different
in silico designs which allows the scientist to quickly select preferred
designs and product format. The underlying software to the new on-line LNA(TM)
gapmer design tool includes important performance parameters such as LNA
spiking pattern, target accessibility, secondary structures and potential
off-targets based on searches against several gene databases including ENSEMBL. 

The design tool is wet-lab validated with hundreds of LNA(TM) gapmer antisense
oligonucleotides having been tested in cell cultures and in animal models. 

New to Exiqon's LNA(TM) longRNA GapmeR product offering is a number of carefully
selected and wet-lab validated negative control assays. 

'The new on-line design tool is perfectly suited for scientists who have
identified interesting targets for instance by next generation sequence
analysis and would like to understand the functionality of such targets' says
Senior Vice President, Sales & Marketing, Henrik M. Pfundheller and continues
'Since the launch of the product line earlier this year we have seen a very
rapid adaptation by our customers which I believe is due to the substantial
body of scientific literature supporting the superior performance of LNA(TM)
gapmers'. 

LNA(TM) longRNA GapmeRs are high affinity antisense oligonucleotides used for
functional analysis that allow researchers to study the gene function and
downstream biological implications of silencing a specific mRNA or long
non-coding RNA (lncRNA) in cell-cultures or animal models. The unique
LNA(TM)-enhanced design of the LNA(TM) longRNA GapmeR offers superior performance
compared to alternative RNA silencing methods including siRNA. Even targets
located in the nucleus are effectively silenced by the LNA(TM) longRNA GapmeRs.  
The incorporation of LNA(TM) increases bio-stability which secures the biological
activity over an extended period of time and provides excellent pharmacokinetic
and pharmacodynamics properties including high stability and low toxicity
making them ideal for in vivo testing. 

Exiqon offers a range of compatible LNA(TM) enhanced products for mRNA and lncRNA
research including products for qPCR and in situ hybridization analysis. 

Information about the LNA(TM) longRNA GapmeRs is available here:
http://www.exiqon.com/gapmers 

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090
2106)
News Source: NASDAQ OMX



03.09.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Exiqon A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0060077758
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------